PeopleProfiling degradation of non-iMiD dependent Znfs
Profiling degradation of non-iMiD dependent Znfs
VistaraBio provides value added services to select pharma and biotechnology clients based on its proprietary knowledge. Differently from traditional CRO service models which do not typically involve service provider IP, VistaraBio will include its proprietary information & craft the engagement on a case-by-case basis depending upon the complexity and deliverables involved in servicing the client.Additional value added assays & value added services:S2T – Target discovery directly from clinical samples.ubCAST – Degrader pharmacology and off-target detection assay.Vistamer – PTM-specific peptide probes for subcellular localization of POI with confocal microscopyneo-PERK – Compound screening for PERK/ISR modulation in cells with null phenotypes for EIF2 alpha, GCN2, GSPT1 or other proteins involved in translation.Profiling degradation of non-iMiD dependent ZnfsMany of the identified Znfs exhibit tissue-specific expression patterns and are mutated in cancer or neurodegenerative diseases. A majority of the C2H2-type Znfs exhibit ‘motifs’ adjacent to the ubiquitination sites, suggesting that their degradation may involve only a few E3 ligases which follow common mechanisms. VistaraBio will commercialize Znfs for therapeutic development in oncology.
active0
Roles
team_member
Timeline
Current Company
